MDACC Study No:2005-0824 ( NCT No: NCT00410059)
Title:A Phase II, Open Label Study of Erlotinib (TarcevaŽ) in
Previously Treated Subjects with Advanced Non-Small Cell Lung Cancer
Principal Investigator:Erminia Massarelli
Treatment Agent:Erlotinib
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if Tarcevaâ (OSI-774,
erlotinib hydrochloride) can help to control NSCLC. The safety of this drug
will also be studied, as well as the drug's effect on different cells in the
body and the participants' overall response.
Hide details for General InformationGeneral Information

Disease Group:Lung
Phase of Study:Phase II
Treatment Agents:Erlotinib
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:N/A
Supported By:N/A
Return Visit:Patients will return to the clinic every 4 weeks.
Home Care:N/A

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Erminia Massarelli
Dept:Thoracic and Head and Neck Med
For Clinical Trial Enrollment:713-792-6363
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults